<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31593">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01662518</url>
  </required_header>
  <id_info>
    <org_study_id>Bramets-01</org_study_id>
    <nct_id>NCT01662518</nct_id>
  </id_info>
  <brief_title>DDS-25 Gauge in Patients With Macular Edema Secondary to Retinal Vein Occlusion (RVO)</brief_title>
  <acronym>DDS-25</acronym>
  <official_title>A Safety and Efficacy Study to Assess DDS-25 Gauge in Patients With Macular Edema Secondary to Retinal Vein Occlusion (RVO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro de Pesquisa Rubens Siqueira</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centro de Pesquisa Rubens Siqueira</source>
  <oversight_info>
    <authority>Brazil: National Committee of Ethics in Research</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone
      (DDS-25) for the treatment of macular edema associated with retinal vein occlusion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluate the effects on visual acuity, electroretinography, fluorescein angiography and
      optical coherence tomography in 10 patients with macular edema associated with retinal vein
      occlusion undergoing intravitreal injection of implant of dexamethasone (DDS-25).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Best Corrected Visual Acuity (BCVA)</measure>
    <time_frame>Day 0 - Day 180</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in central foveal thickness at 48 weeks</measure>
    <time_frame>1 day to 48 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Macular Edema</condition>
  <condition>Retinal Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>DDS-25</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreal injection of DDS-25(Dexamethasone drug delivery system )</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dexamethasone drug delivery system (DDS-25)</intervention_name>
    <description>350 mg Dexamethasone posterior segment drug delivery system (DDS-25) injection into the vitreous cavity at baseline</description>
    <arm_group_label>DDS-25</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older with macular edema resulting from retinal vein occlusion

          -  Decrease in visual acuity in at least one eye as a result of macular edema (20/50 or
             worse)

          -  Visual acuity in other eye no worse than 20/200

        Exclusion Criteria:

          -  Known anticipated need for ocular surgery within next 12 months

          -  History of glaucoma or current high eye pressure requiring more than 1 medication

          -  Diabetic retinopathy

          -  Uncontrolled systemic disease

          -  Known steroid-responder

          -  Use of systemic steroids

          -  Use of warfarin/heparin
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rubens C Siqueira, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro de Pesquisa Rubens Siqueira</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rubens C Siqueira, MD,PhD</last_name>
    <phone>55(17)32140896</phone>
    <email>rubenssiqueira@terra.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rubens C Siqueira, MD,PhD</last_name>
    <phone>55(17)32345858</phone>
    <email>rubenssiqueira@terra.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centro de Pesquisa Rubens Siqueira</name>
      <address>
        <city>Sao Jose do Rio Preto</city>
        <state>SP</state>
        <zip>15010-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rubens C Siqueira, MD,PhD</last_name>
      <phone>55(17)32345858</phone>
      <email>rubenssiqueira@terra.com.br</email>
    </contact>
    <investigator>
      <last_name>Rubens C Siqueira, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 9, 2012</lastchanged_date>
  <firstreceived_date>August 8, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centro de Pesquisa Rubens Siqueira</investigator_affiliation>
    <investigator_full_name>Rubens Camargo Siqueira</investigator_full_name>
    <investigator_title>MD,PhD - Principal Investigator</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
